Lee SY, Lin YC, Chen CP, Cheng SH, et al. Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. PLoS One 2024;19:e0314003.
PMID: 39565750